| P50 | author | Paul Workman | Q7154482 |
| | Debra J. Skene | Q38546285 |
| | Udai Banerji | Q41195747 |
| P2093 | author name string | Johann S de Bono | |
| | Alexis de Haven Brandon | |
| | Florence I Raynaud | |
| | Gary Box | |
| | Melanie Valenti | |
| | Suzanne A Eccles | |
| | Alan T Henley | |
| | Joo Ern Ang | |
| | Valerie Meresse | |
| | Victoria L Revell | |
| | Stanley B Kaye | |
| | Ruediger Rueger | |
| | Akos Pal | |
| | Miro Venturi | |
| | Yasmin J Asad | |
| P2860 | cites work | BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma | Q38498046 |
| | Phosphoproteomics Reveals MAPK Inhibitors Enhance MET- and EGFR-Driven AKT Signaling in KRAS-Mutant Lung Cancer. | Q38757884 |
| | MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition | Q39007170 |
| | Identification of human plasma metabolites exhibiting time-of-day variation using an untargeted liquid chromatography-mass spectrometry metabolomic approach. | Q39581478 |
| | Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells | Q42478581 |
| | Urokinase-type plasminogen activator receptor is associated with macrophages and plaque rupture in symptomatic carotid atherosclerosis. | Q46349915 |
| | Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma | Q24597152 |
| | A landscape of driver mutations in melanoma | Q24603357 |
| | Melanoma: oncogenic drivers and the immune system | Q26775598 |
| | Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent | Q27666709 |
| | Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial | Q27851856 |
| | Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations | Q27853023 |
| | First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors | Q27853088 |
| | Mutations of the BRAF gene in human cancer | Q27860760 |
| | Critical parameters in targeted drug development: the pharmacological audit trail | Q28076617 |
| | ras oncogenes in human cancer: a review | Q29547769 |
| | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer | Q29618155 |
| | The RAF proteins take centre stage | Q29620153 |
| | Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis | Q31127142 |
| | Guidelines for the welfare and use of animals in cancer research | Q33903753 |
| | Effect of sleep deprivation on the human metabolome | Q33972140 |
| | Activation of neutral-sphingomyelinase, MAPKs, and p75 NTR-mediating caffeic acid phenethyl ester-induced apoptosis in C6 glioma cells | Q34486274 |
| | Plasma Metabolomic Changes following PI3K Inhibition as Pharmacodynamic Biomarkers: Preclinical Discovery to Phase I Trial Evaluation | Q37660266 |
| | Mitogenic effects of phosphatidylcholine nanoparticles on MCF-7 breast cancer cells. | Q37688019 |
| | BRAF, a target in melanoma: implications for solid tumor drug development | Q37772444 |
| | BRAFV600E: implications for carcinogenesis and molecular therapy | Q37851238 |
| | MAPK pathway inhibition in melanoma: resistance three ways | Q38238597 |
| | Targeting RAS-ERK signalling in cancer: promises and challenges | Q38272894 |
| | Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244) | Q38300326 |
| P433 | issue | 10 | |
| P921 | main subject | pharmacodynamics | Q725307 |
| | biomarker | Q864574 |
| P304 | page(s) | 2315-2323 | |
| P577 | publication date | 2017-06-21 | |
| P1433 | published in | Molecular Cancer Therapeutics | Q2363144 |
| P1476 | title | Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma | |
| P478 | volume | 16 | |